A few weeks back, I highlighted the positive change at the top of Aspreva Phamarceuticals - the appointment of J. William Freytag, PhD as CEO. In just a few weeks since Freytag's appointment, Aspreva announced a restructuring the company claims is intended for long-term future growth. The current chief scientific officer, Dr. Richard Jones, will be leaving the company. His responsibilities will be assumed by Dr. Usman Azam, Aspreva's Chief Medical Officer. The company also plans to reduce staffing levels worldwide by 25%.
For more see:
Press Release
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment